Business Wire

With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?

26.11.2025 08:00:00 CET | Business Wire | Press Release

Share

An international survey, spanning Australia, France, Japan, Poland and the UK, has found that many employees experiencing fertility challenges lack support in the workplace, with almost two in five (39%) leaving or considering leaving their roles while undergoing treatment.1

‘The Impact of Fertility Challenges at Work: International Insights’ survey by Ferring Pharmaceuticals, Fertility Matters at Work and This Can Happen shows that, despite growing awareness of reproductive health, two thirds (67%) who have experienced fertility challenges say that their workplaces do not offer support for employees undergoing fertility treatment, with France the least likely to provide it (88%).1 60% said they were not clearly entitled to time off for fertility appointments, with time recorded as paid leave, unpaid leave or annual leave (26%), and some also reported taking sick leave due to a lack of flexibility (17%).1

With assisted reproduction therapy, including IVF, already accounting for up to 12% of births in some countries,2,3,4,5 employee expectations are rapidly shifting. 73% of those experiencing fertility challenges say they would be attracted to a role that provides fertility support, reinforcing the need for clearer, more consistent workplace policies.1

A large gap also emerged regarding the impact of going through fertility treatment. While three quarters (75%) of employers feel their organisation acknowledges fertility treatment as a significant life event, only 27% of employees who have experienced fertility challenges agree.1 As a result, more than a fifth (22%) currently felt unsupported by their organisation, rising to 38% in Poland, and more than a third (36%) have felt pressure from their employer to be at work while undergoing treatment or investigations.1

Mental health impact was one of the most consistent themes across all countries. 94% of employees reported that fertility treatment affects their mental wellbeing, with 80% experiencing anxiety or depression during their fertility journey.1

However, the survey did show that practice is starting to change with signs employers recognise the importance of fertility support on employee engagement and talent attraction. 58% either already include fertility and family-building challenges as part of their workforce engagement and wellbeing strategy or will be in the future.1

“At Ferring, we believe that every individual deserves compassionate and practical support during their fertility journey. This research highlights the challenges employees face and reinforces the importance of clear policies, open conversations and workplace cultures that recognise fertility as a significant moment in people’s lives,” said Christelle Beneteau, Chief People Officer, Ferring.

“Fertility treatment is a challenging time, yet the report shows that many people are still navigating it without the support they need, from manager training and awareness, to entitled leave,” said Becky Kearns, Co-Founder of Fertility Matters at Work. “We have seen first-hand how employees who receive fertility support feel more committed to their employer. More workplace recognition and clearer fertility policies could make a huge difference for individuals and organisations, with those who feel supported less likely to leave their jobs.”

“Mental wellbeing and fertility challenges are deeply connected, yet too often overlooked in workplace strategies. This research shows that creating supporting cultures and clear support policies isn’t just compassionate – it’s essential for retaining talent and protecting mental health,” said Kathryn Courtenay-Evans, This Can Happen.

Given that infertility now affects roughly one in six people globally,6 the report makes it clear that workplaces must urgently transform how they support people navigating fertility treatment. This means proactively creating inclusive, open, and supportive cultures, and implementing clear fertility policies to ensure consistent guidance and access to support.

About ‘The Impact of Fertility Challenges at Work: International Insights’ survey

Jointly run by Fertility Matters at Work (FMAW), This Can Happen, and Ferring Pharmaceuticals and funded by Ferring, the survey aims to explore how fertility challenges impact people in the workplace and how employers can offer better support. The survey, of over 3,600 employees and employers, was initially conducted in the UK and has since been rolled out to Australia, Japan, Poland and France.

Report link: The Impact of Fertility Challenges at Work: International Insights

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide.

About Fertility Matters at Work

Fertility Matters at Work is the leading training provider for fertility support in the workplace.

About This Can Happen

This Can Happen is your trusted partner to support mental wellbeing in your workplace.

1 Ferring/Fertility Matters at Work/This Can Happen. 2025. Data on file

2 Newman JE, et al. Assisted reproductive technology in Australia and New Zealand 2022. Available at: https://www.unsw.edu.au/content/dam/pdfs/medicine-health/npesu/research-reports/2024-09-npesu/2024-09-assisted-reproductive-technology-in-australia-and-new-zealand-2022.pdf. Last accessed: November 2025.

3 Centers for Disease Control and Prevention. National ART Surveillance. Available at: https://www.cdc.gov/art/php/surveillance/index.html. Last accessed: November 2025.

4 BBC. Why is IVF so popular in Denmark? Available at: www.bbc.co.uk/news/world-europe-45512312. Last accessed: November 2025.

5 IVIRMA. SEF 2022 Report Data. Available at: http://iviglobaleducation.com/en/12-of-births-in-spain-are-due-to-assisted-reproduction-sef-2022-report-data. Last accessed: November 2025.

6 World Health Organization. Infertility data. Available at: www.who.int/health-topics/infertility#tab=tab_1. Last accessed: November 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20251125104720/en/

Contacts

Matthew Worrall
Director of Corporate Communications, Ferring
+44 7442 271 811
matthew.worrall@ferring.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye